Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
Tag Archive for: Oncology
This approval marks the third indication for Keytruda in cervical cancer and the 39th indication for Keytruda in the United States.
As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.
Today the company said it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.
Japan’s Astellas Pharma said the agency declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer.
Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as “guided missiles” to target cancer cells and minimize damage to healthy tissue.
The U.S. drugmaker has been doubling down on building future revenue streams as its blockbuster immunotherapy, Keytruda, inches closer to losing key patents, opening the doors for competition from biosimilars.
Yesterday’s dual agreements with Umoja continues AbbVie’s dealmaking spree in late 2023, which saw the pharma ink two multibillion-dollar agreements. The first was with ImmunoGen and its deep portfolio of antibody-drug conjugates (ADC), which AbbVie bought for $10.1 billion.
The deal will see Roche gain access to MOMA’s platform, known as KnowledgeBase, to find new drugs to go after cancer cell growth and survival.
Iovance’s lifileucel for advanced melanoma and Madrigal’s resmetirom for nonalcoholic steatohepatitis are just a couple of the key decisions on the FDA’s docket this quarter.
